Intracameral Vigamox® (Moxifloxacin 0.5%) is not effective in preventing endophthalmitis in a rabbit model [1]

American Journal of Ophthalmology

Volumn 141, Issue 4, 2006, Pages 777-

  Kodjikian, Laurent ^a   Garweg, Justus G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ANTERIOR EYE CHAMBER; CORNEA ENDOTHELIUM; DRUG EFFICACY; ENDOPHTHALMITIS; INTRAOCULAR PRESSURE; LETTER; NONHUMAN; PRIORITY JOURNAL; TOXICITY; ANIMAL; BACTERIAL COUNT; BACTERIAL EYE INFECTION; DISEASE MODEL; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; INJECTION; MICROBIOLOGY; NOTE; RABBIT; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTERIOR CHAMBER; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; INJECTIONS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS;

EID: 33645313823     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2005.11.014     Document Type: Letter

References (1)

1. R.P. Kowalski, E.G. Romanowski, F.S. Mah, K.A. Yates, Y.J. Gordon Intracameral Vigamox® (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model Am J Ophthalmol 140 2005 497 504